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Summary. Desferrioxamine (DFX) alone (40–50 mg/kg/d
s.c. over 8–12 h, five times weekly) was compared with
combined DFX twice weekly and deferiprone (75 mg/kg/d)
over 12 months in previously poorly chelated thalassaemia
patients. Serum ferritin fell from 5506 ± 635 lg/l (mean ±
SEM) to 3998 ± 604 lg/l (P < 0Æ001; n ¼ 14) in the DFX
group and from 4153 ± 517 lg/l to 2805 ± 327 lg/l in
the combined group (P < 0Æ01; n ¼ 11). Deferiprone plus
DFX produced a greater mean urine iron excretion
(1Æ01 mg/kg/24 h) than iron intake from blood transfusion
in each patient. Main side-effects were skin reactions (DFX
alone), nausea and arthralgia (combined therapy). As che-
lation therapy, the combined protocol was as effective as
DFX five times weekly.
Keywords: deferiprone, desferrioxamine, thalassaemia, iron
chelation.
Desferrioxamine (DFX) is currently the only iron-chelating
agent approved for initial clinical use in Europe for
transfusional iron overload, as found in patients with
thalassaemia major. Many patients find difficulty in com-
plying with daily subcutaneous DFX administration and
over 90% of patients worldwide cannot afford adequate
doses of DFX.
Thus there is a great need for an effective and safe oral
iron-chelating drug. Deferiprone (1,2-dimethyl-3-hydroxy-
pyrid-4-one) has been shown to be active in many studies
(Barman Balfour & Foster, 1999). At a dose of 75 mg/kg
body weight daily, it appears to maintain the body iron
burden at a safe level, as assessed by liver biopsy, in some
but not all patients with transfusional iron overload
(Hoffbrand et al, 1998; Olivieri et al, 1998). Previous studies
have shown that deferiprone and DFX are effective given on
the same day (Wonke et al, 1998; Balveer et al, 2000). The
aim of the present study was to investigate whether a
combination of 75 mg/kg of deferiprone with subcutaneous
twice weekly infusions of DFX over a 12-month period could
improve iron status, as assessed by changes in serum
ferritin, in severely iron-overloaded previously poorly
chelated patients.
PATIENTS AND METHODS
We studied 25 patients with transfusion-dependent thalas-
saemia major (age 12–40 years) who were attending the
Chronic Care Centre in Beirut. Each received regular
transfusions of packed red cells every 3 to 4 weeks to
maintain a haemoglobin concentration above 9 g/dl. Before
enrolment, all patients were non-compliant or unable to
afford DFX and were receiving DFX subcutaneously less
than 4 d weekly and had serum ferritin levels > 3000 lg/l.
They were randomly assigned to receive DFX at a daily dose
of 40–50 mg/kg/d by subcutaneous infusion for 8–12 h
on five to seven nights each week, or deferiprone (Lipomed,
Basel, Switzerland) 75 mg/kg body weight in three divided
oral doses before meals and DFX 2 g/d by subcutaneous
infusion overnight for 8–12 h twice weekly. Eleven patients
completed 12 months of combined therapy and 14 patients
completed 12 months of DFX alone. Compliance with both
regimens was improved by weekly hospital visits for the first
3 months and monthly visits thereafter with encourage-
ment from dedicated medical and nursing staff. Also the
drugs, previously to be purchased by the patient, were
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supplied free. Compliance was assessed by the number of
vials of DFX or tablets of deferiprone used. Safety was
determined by detailed clinical and laboratory examination.
Patients were also asked to complete questionnaires about
any side-effects they experienced.
Serum ferritin concentrations were measured at 6 and
12 months. Urinary iron excretion (UIE) over a 24-h period
was measured at 1 and 12 months on the combined
therapy. Full blood count, liver and renal function were
performed weekly for 3 months and then monthly. Statis-
tical analysis was performed using the Wilcoxon rank test
for unpaired data and Wilcoxon signed rank test for paired
data. The study was approved by the Ethical Committee of
the Chronic Care Centre, Beirut.
RESULTS
There were no significant differences in the initial serum
ferritin levels, age, sex distribution or the amount of blood
transfused between the two groups (Wilcoxon sum rank
test).
Efficacy
DFX. In the 14 patients receiving DFX, serum ferritin
levels showed a decrease from 5506 ± 635 lg/l (mean ±
SEM) to 4856 ± 699 lg/l at 6 months (P ¼ 0Æ07) and to
3998 ± 604 lg/l at 12 months (P < 0Æ001) (Table I).
Deferiprone and DFX. In the 11 patients receiving deferi-
prone each day and DFX on 2 d each week, serum ferritin
levels dropped from 4153 ± 517 lg/l to 3005 ± 393 lg/l
at 6 months (P < 0Æ02) and to 2805 ± 327 lg/l at
12 months (P < 0Æ01) (Table II). UIE was a mean of
49Æ3 ± 5Æ5 mg at 1 month and had fallen to 22Æ9 ±
5Æ8 mg at 12 months (P < 0Æ01). At 1 month, all the
patients excreted more iron in response to combined
treatment than their calculated iron intake from blood
transfusion (Table II).
Side-effects
No patient showed any change in physical examination,
absolute neutrophil count, serum urea, creatinine or liver
Table II. Patient characteristics and effect of deferiprone (75 mg/kg/d) + DFX (2 g/d twice weekly) on serum ferritin levels and urinary iron
excretion.
Age/sex HCV
Transfused
units/year
Iron intake
(mg/kg/24 h)
Serum ferritin (lg/l) UIE mg/24 h (mg/kg/24 h)
Initial 6 months 12 months 1 month 12 months
19/M – 12Æ6 0Æ16 4029 6091 1970 86Æ2 (1Æ80) 20Æ3 (0Æ43)
13/M – 33 0Æ37 3525 3236 3338 48Æ8 (0Æ90) 78Æ4 (1Æ45)
15/M – 25 0Æ36 3655 3179 2214 56Æ2 (1Æ31) 11Æ9 (0Æ28)
14/F – 20 0Æ30 3021 1032 443 76Æ6 (2Æ02) 28Æ3 (0Æ74)
12/F + 23 0Æ22 3011 2240 2771 33Æ9 (0Æ71) 26Æ1 (0Æ54)
17/M – 27 0Æ26 9171 1915 2199 48Æ3 (0Æ77) 12Æ8 (0Æ20)
40/M – 34 0Æ39 3230 2119 3261 37Æ2 (0Æ69) 21Æ8 (0Æ40)
14/M – 33 0Æ39 3766 2788 3456 26Æ8 (0Æ51) 9Æ0 (0Æ17)
15/M + 33 0Æ40 4277 3456 3664 31Æ9 (0Æ61) 8Æ2 (0Æ16)
12/F – 23 0Æ18 3976 3155 1977 49Æ5 (0Æ82) 22Æ8 (0Æ38)
12/F – 25 0Æ30 4022 3852 4568 46Æ9 (0Æ94) 20Æ2 (0Æ40)
Mean (SEM) 29 4153 (517) 3005* (393) 2805 (327) 49Æ3 (5Æ5) 22Æ9 (5Æ8)
Mean (SEM) 0Æ31 (0Æ08) 1Æ01 (0Æ11) 0Æ47 (0Æ09)
*P < 0Æ02 compared with initial ferritin.
P < 0Æ01 compared with initial ferritin.
P < 0Æ001 compared with 1 month (Wilcoxon signed rank test).
UIE, urinary iron excretion.
Table I. Patient characteristics and the effect of DFX alone on ser-
um ferritin levels.
Age
(years)/sex HCV
Serum ferritin (lg/l)
Initial 6 months 12 months
18/F + 3411 2669 1654
17/F – 3029 1600 1958
14/M – 4127 2902 2780
19/F – 10041 11734 4713
16/F + 10564 8213 8249
12/M – 3968 3695 3156
12/F – 5020 4482 3073
16/M – 3150 3428 1499
17/M – 7678 4530 8097
16/F – 5768 5544 4801
17/F – 5740 3345 5176
21/M – 4929 5293 4731
16/F – 4300 6759 5014
15/M – 5361 3800 1080
5506 (635) 4856 (699) 3998* (644)
*P < 0Æ001 compared with initial serum ferritin levels (Wilcoxon
signed rank test).
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biochemistry. The most common side-effect in patients
receiving DFX alone was pain, itching, erythema, swelling
and induration at the site of infusion in 12 (85Æ7%) of the
14 patients. The most common adverse effect in the
combined therapy group was nausea, especially in the first
month of treatment, in five patients (45Æ4%). Joint pain,
stiffness or swelling occurred in three patients (27Æ3%), but
it was transient and easily treated with non-steroidal anti-
inflammatory drugs. None required discontinuation of
deferiprone. Other possible side-effects included fatigue
(one patient), loss of appetite (one patient), headache (three
patients), transient skin rash (two patients) and abdominal
discomfort (two patients), none of which required discon-
tinuation of therapy.
Compliance
In patients receiving the combined therapy, compliance was
excellent (arbitrarily defined as taking > 90% of the recom-
mended doses) in 10 patients and good (75–90% of
recommended doses) in one patient, as assessed by the
patient’s history, parental evidence and usage of tablets
provided in just sufficient quantities between check-up
visits. In patients receiving DFX alone, compliance was
considered to be excellent in 11 patients and good in three
patients, as assessed mainly by counting the vials given to,
and returned by, the patients.
DISCUSSION
The results of this study confirm that thalassaemia patients
with severe iron overload can be safely treated with a
combination of daily deferiprone at a dose of 75 mg/kg/d
and DFX at a dose of 2 g given over 8–10 h on 2 d/week for
1 year. This combined therapy was effective in reducing
iron burden, as assessed by serum ferritin levels. These
findings are in accordance with previous studies by Wonke
et al (1998) and Balveer et al (2000). Recent evidence
suggests that deferiprone may serve as a shuttle, entering
cells and bringing iron from tissue compartments to the
blood stream where it is then transferred to DFX, which is
given simultaneously, and excreted bound to DFX (Breuer
et al, 2001).
Deferiprone (75 mg/kg/d) has resulted in falls of serum
ferritin levels in some but not all studies (Barman Balfour
& Foster, 1999). Wonke et al (1998) showed that increasing
the dose of deferiprone from 75 mg/kg/d to a mean of
85 mg/kg/d for 6 months resulted in a significant fall in
serum ferritin in nine thalassaemia patients. Alternatively,
the combination of deferiprone (75 mg/kg/d) and DFX at a
dose of 2 g/d twice a week may be tried. In our patients, the
combined therapy was more effective, as assessed by
reduction in serum ferritin levels and UIE, than deferiprone
75 mg/kg given alone in a previous similar group of
patients (Taher et al, 2001). In those 11 patients of similar
age to the 11 receiving combined therapy studied here and
also with serum ferritin levels > 3000 lg/l and non-
compliant with DFX, the mean serum ferritin level fell at
12 months from 5061 to 4098 lg/l. This fall was not
significant and in three of the 11 patients, the serum ferritin
rose during the study period. In that study, the mean initial
UIE in response to deferiprone alone was 23Æ9 mg in 24 h
compared with 49Æ3 mg in 24 h in the 11 patients receiving
combined therapy studied here. After 1 month on combined
therapy, the UIE was sufficient to put all of them into
negative iron balance (Table II).
The combined therapy was well tolerated, and reduction
or cessation of deferiprone therapy was not required
because of adverse effects in any patient. The incidence of
various side-effects was similar to our findings in a similar
group of patients treated with deferiprone alone. In conclu-
sion, combined therapy with deferiprone and DFX, provi-
ding larger and longer term prospective trials do not show
any increased incidence of toxicity, may be the best method
in many transfusion-dependent patients for achieving
satisfactory iron chelation therapy with good, long-term
patient compliance.
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